MedImmune venture capital arm leads financing of cancer drug developer G1
This article was originally published in Scrip
Executive Summary
MedImmune Ventures led a $12.5 million financing of closely held cancer therapy developer G1 Therapeutics, funding that will potentially help the startup take its lead drug into clinical testing.